| Ms Stephanie A Estes, CRNM | |
|
221 W Stewart Ave Ste 101, Medford, OR 97501-3609 | |
| (541) 690-3500 | |
| (541) 842-2210 |
| Full Name | Ms Stephanie A Estes |
|---|---|
| Gender | Female |
| Speciality | Certified Nurse Midwife (cnm) |
| Experience | 8 Years |
| Location | 221 W Stewart Ave Ste 101, Medford, Oregon |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1003357401 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367A00000X | Advanced Practice Midwife | 201905832NP-PP (Oregon) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| La Clinica Del Valle Family Health Care Center Inc | 0244143089 | 43 |
News Archive
More than 230,000 women will be diagnosed with breast cancer in the U.S. this year, a diagnosis that comes with treatment choices that can be overwhelming to patients and complex to their doctors. But what if there was only one treatment for your breast cancer? And what if it was based on your genetics and specific cancer type in the hope of maximizing its effectiveness?
Rapid Micro Biosystems, a leading provider of automated, non-destructive, rapid microbial detection, today announced that it has signed a contract with the Biomedical Advanced Research and Development Authority (BARDA) for the development of rapid sterility testing for vaccines as part of the Innovative Platform Technologies program of BARDA's Strategic Science and Technology Division.
A new study published on the medRxiv* pre-print server and currently undergoing peer-review aims to answer this question through whole blood transcriptomics of individuals with varying degrees of COVID-19 severity. Transcriptomics, done by RNA sequencing, gives insights into the genes expressed in a cell at a given time point. It gives an analysis of all RNA molecules within a cell, in this case, whole blood.
Zealand Pharma A/S, the biopharmaceutical company dedicated to the discovery and development of innovative peptide-based drugs, is pleased to note that its partner, sanofi-aventis, has today announced positive top-line results of the Phase III GETGOAL-L-ASIA trial which assessed the efficacy and safety of lixisenatide, a once-daily GLP-1 receptor agonist discovered by Zealand Pharma, in combination with basal insulin.
For American hospitals, "the cost of doing nothing in Washington translates into tens of billions of dollars each year in medical bills that go unpaid by patients with little or no insurance," The New York Times reports.
› Verified 7 days ago
| Entity Name | La Clinica Del Valle Family Health Care Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1851327571 PECOS PAC ID: 0244143089 Enrollment ID: O20031107000627 |
News Archive
More than 230,000 women will be diagnosed with breast cancer in the U.S. this year, a diagnosis that comes with treatment choices that can be overwhelming to patients and complex to their doctors. But what if there was only one treatment for your breast cancer? And what if it was based on your genetics and specific cancer type in the hope of maximizing its effectiveness?
Rapid Micro Biosystems, a leading provider of automated, non-destructive, rapid microbial detection, today announced that it has signed a contract with the Biomedical Advanced Research and Development Authority (BARDA) for the development of rapid sterility testing for vaccines as part of the Innovative Platform Technologies program of BARDA's Strategic Science and Technology Division.
A new study published on the medRxiv* pre-print server and currently undergoing peer-review aims to answer this question through whole blood transcriptomics of individuals with varying degrees of COVID-19 severity. Transcriptomics, done by RNA sequencing, gives insights into the genes expressed in a cell at a given time point. It gives an analysis of all RNA molecules within a cell, in this case, whole blood.
Zealand Pharma A/S, the biopharmaceutical company dedicated to the discovery and development of innovative peptide-based drugs, is pleased to note that its partner, sanofi-aventis, has today announced positive top-line results of the Phase III GETGOAL-L-ASIA trial which assessed the efficacy and safety of lixisenatide, a once-daily GLP-1 receptor agonist discovered by Zealand Pharma, in combination with basal insulin.
For American hospitals, "the cost of doing nothing in Washington translates into tens of billions of dollars each year in medical bills that go unpaid by patients with little or no insurance," The New York Times reports.
› Verified 7 days ago
| Entity Name | Obhg Oregon Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1528585148 PECOS PAC ID: 2365776390 Enrollment ID: O20190626000182 |
News Archive
More than 230,000 women will be diagnosed with breast cancer in the U.S. this year, a diagnosis that comes with treatment choices that can be overwhelming to patients and complex to their doctors. But what if there was only one treatment for your breast cancer? And what if it was based on your genetics and specific cancer type in the hope of maximizing its effectiveness?
Rapid Micro Biosystems, a leading provider of automated, non-destructive, rapid microbial detection, today announced that it has signed a contract with the Biomedical Advanced Research and Development Authority (BARDA) for the development of rapid sterility testing for vaccines as part of the Innovative Platform Technologies program of BARDA's Strategic Science and Technology Division.
A new study published on the medRxiv* pre-print server and currently undergoing peer-review aims to answer this question through whole blood transcriptomics of individuals with varying degrees of COVID-19 severity. Transcriptomics, done by RNA sequencing, gives insights into the genes expressed in a cell at a given time point. It gives an analysis of all RNA molecules within a cell, in this case, whole blood.
Zealand Pharma A/S, the biopharmaceutical company dedicated to the discovery and development of innovative peptide-based drugs, is pleased to note that its partner, sanofi-aventis, has today announced positive top-line results of the Phase III GETGOAL-L-ASIA trial which assessed the efficacy and safety of lixisenatide, a once-daily GLP-1 receptor agonist discovered by Zealand Pharma, in combination with basal insulin.
For American hospitals, "the cost of doing nothing in Washington translates into tens of billions of dollars each year in medical bills that go unpaid by patients with little or no insurance," The New York Times reports.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Ms Stephanie A Estes, CRNM 931 Chevy Way, Medford, OR 97504-4127 Ph: (541) 690-3555 | Ms Stephanie A Estes, CRNM 221 W Stewart Ave Ste 101, Medford, OR 97501-3609 Ph: (541) 690-3500 |
News Archive
More than 230,000 women will be diagnosed with breast cancer in the U.S. this year, a diagnosis that comes with treatment choices that can be overwhelming to patients and complex to their doctors. But what if there was only one treatment for your breast cancer? And what if it was based on your genetics and specific cancer type in the hope of maximizing its effectiveness?
Rapid Micro Biosystems, a leading provider of automated, non-destructive, rapid microbial detection, today announced that it has signed a contract with the Biomedical Advanced Research and Development Authority (BARDA) for the development of rapid sterility testing for vaccines as part of the Innovative Platform Technologies program of BARDA's Strategic Science and Technology Division.
A new study published on the medRxiv* pre-print server and currently undergoing peer-review aims to answer this question through whole blood transcriptomics of individuals with varying degrees of COVID-19 severity. Transcriptomics, done by RNA sequencing, gives insights into the genes expressed in a cell at a given time point. It gives an analysis of all RNA molecules within a cell, in this case, whole blood.
Zealand Pharma A/S, the biopharmaceutical company dedicated to the discovery and development of innovative peptide-based drugs, is pleased to note that its partner, sanofi-aventis, has today announced positive top-line results of the Phase III GETGOAL-L-ASIA trial which assessed the efficacy and safety of lixisenatide, a once-daily GLP-1 receptor agonist discovered by Zealand Pharma, in combination with basal insulin.
For American hospitals, "the cost of doing nothing in Washington translates into tens of billions of dollars each year in medical bills that go unpaid by patients with little or no insurance," The New York Times reports.
› Verified 7 days ago
Linda D Osborne, CNM Advanced Practice Midwife Medicare: Not Enrolled in Medicare Practice Location: 940 Royal Ave, Suite 350, Medford, OR 97504 Phone: 541-732-7460 Fax: 541-732-7461 | |
Caraway L Timmins, CNM, MSN Advanced Practice Midwife Medicare: Not Enrolled in Medicare Practice Location: 3617 S Pacific Hwy, Medford, OR 97501 Phone: 541-535-6239 Fax: 541-535-4377 | |
Rebecca Rose, CNM Advanced Practice Midwife Medicare: Accepting Medicare Assignments Practice Location: 221 W Stewart Ave Ste 101, Medford, OR 97501 Phone: 541-690-3555 | |
Ireli Yudith Hernandez, Advanced Practice Midwife Medicare: Accepting Medicare Assignments Practice Location: 221 W Stewart Ave Ste 101, Medford, OR 97501 Phone: 541-690-3500 | |
Nancy Seulean, CNM Advanced Practice Midwife Medicare: Not Enrolled in Medicare Practice Location: 940 Royal Ave, Suite 350, Medford, OR 97504 Phone: 541-732-7460 Fax: 541-732-7461 | |
Betty Kay Taylor, NMNP Advanced Practice Midwife Medicare: Not Enrolled in Medicare Practice Location: 940 Royal Ave, Ste 350, Medford, OR 97504 Phone: 541-732-7460 Fax: 541-732-7461 |